An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies
Latest Information Update: 16 Oct 2025
At a glance
- Drugs IPN 01203 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Ipsen
Most Recent Events
- 16 Oct 2025 New trial record